Moderna granted fda breakthrough therapy designation for mrna-1345, an investigational respiratory syncytial virus (rsv) vaccine candidate

Designation based on positive topline data from the conquerrsv phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against rsv lower respiratory tract disease, defined by 2 or more symptoms in older adults cambridge, ma / accesswire / january 30, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced mrna-1345, an investigational mrna vaccine candidate for respiratory syncytial virus (rsv), has been granted breakthrough therapy designation by the u.s. food and drug administration (fda) for the prevention of rsv-associated lower respiratory tract disease (rsv-lrtd) in adults aged 60 years or older. the designation was based on positive topline data from the conquerrsv phase 3 pivotal efficacy trial.
MRNA Ratings Summary
MRNA Quant Ranking